Remove Clinical Development Remove Protein Expression Remove Protein Production Remove Therapies
article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It It was by Nicholas Field, Principal Scientist, Purification Development, Lonza, titled: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Christopher Rowley, PhD, Principal Research Scientist, Protein Science Pipeline, Immunocore, on: ‘ImmTAC: A high-affinity soluble TCR bispecific platform to target cancers’. Jürgen Kuball, PhD, Head, Hematology, University Medical Center Utrecht, on: ‘gdT cell inspired therapies’.